Baldwin Sets Jan. 6 Vote on $32.50/Share Sequence-DFO Take-Private
BWIN has more than doubled off its 52-week low of $15.88.
Summary
Baldwin filed the definitive proxy for its $32.50-per-share cash take-private by Sequence and DFO, setting a January 6, 2027 shareholder vote after the HSR waiting period expired November 4, 2026.
Key Events · M&A and Partnerships · BWIN
-
Special Meeting Set for January 6, 2027
Shareholders of record on November 12, 2026 will vote on the merger agreement, an adjournment proposal and advisory golden parachute compensation; the board unanimously recommends approval.
-
$32.50 Cash Per Share Unchanged
Each Class A share converts into $32.50 in cash, an 87.5% premium to the $17.33 unaffected close on June 17, 2026 and 9.6% above the $29.65 close on September 11, 2026.
-
HSR Waiting Period Expired November 4
The 30-day HSR waiting period following the October 5, 2026 filings expired, leaving the shareholder vote and state insurance change-of-control approvals as the main remaining conditions.
-
$7.7 Billion Funding Package Committed
DFO committed up to $4,599,000,000 of equity ($965 million senior plus $3,634 million common) alongside $2,750,000,000 of term loans, a $415,000,000 delayed draw facility and a $500,000,000 revolver; the deal has no financing condition.
Analysis · BWIN · Finance
The definitive proxy now puts the $32.50-per-share cash buyout in front of shareholders, with a special meeting set for January 6, 2027. Deal economics are unchanged from the September 14 announcement, but the document locks in the timeline and confirms the path is clear: the HSR waiting period expired November 4, 2026, leaving the shareholder vote as the only remaining major hurdle. It also quantifies what holders are being asked to approve: a $7.7 billion total funding package ($4.599 billion of DFO equity plus roughly $3.1 billion of debt), a $170.3 million break fee, and a $298.5 million capped TRA termination payment that the special committee negotiated to add $0.50 per share. With the stock at $32.15 against a $32.50 deal price, the market is pricing in a small but real chance the vote or remaining insurance approvals slip.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BWIN was trading at $32.15 on NASDAQ in the Finance sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $15.88 to $32.71. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.